Anti-IL1 therapy in patients with refractory FMF living inGermany

by Buhl, B, Lorenz, H-M, Blank, N
Published 2015

Induction of apoptosis by polyamine metabolites in immunocompetent cells and different tumor cell lines

by Lorenz, H-M, Schiller, M, Gabler, C, Blank, N, Kriegel, M, Winkler, S, Kalden, JR
Published 2002

PW03-029 – Risk factors for AA-type amyloidosis in Germany

by Blank, N, Lohse, P, Hegenbart, U, Lorenz, H-M, Schoenland, SO
Published 2013

12.4 ACZ885 (canakinumab), a new IL-1 beta blocking monoclonal antibody provides long-lasting remission in children with cryopyrin associated periodic syndrome (CAPS)

by Kümmerle-Deschner, J, Blank, N, Roesler, J, Ramos, E, Tzaribachev, N, Gramlich, K, Well, C, Felix, SD, Rordorf, C, Jung, T
Published 2008

Genes responding to Canakinumab therapy in SJIA are -inversely - disregulated in adult onset Still's disease

by Brachat, A, Feist, E, Behrens, F, Blank, N, Nirmala, NR, Specker, C, Witt, M, Zernicke, J, Martini, A, Junge, G
Published 2015

Proinflammatory and prothrombotic effects on human vascular endothelial cells of Immune-cell-derived LIGHT

by Celik, S, Shankar, V, Richter, A, Hippe, H-J, Akhavanpoor, M, Bea, F, Erbel, C, Urban, S, Blank, N, Wambsganss, N, Katus, HA, Dengler, TJ
Published 2009

PReS-FINAL-2331: Low-penetrance NLRP3 variants

by Endres, T, Hofer, F, Goldbach-Mansky, R, Hoffman, HM, Blank, N, Krause, K, Rietschel, C, Horneff, G, Lohse, P, Kuemmerle-Deschner, J
Published 2013

PReS-FINAL-2224: Canakinumab treatment regimens in CAPS-patients

by Hofer, F, Endres, T, Kortus-Götze, B, Blank, N, Weißbarth-Riedel, E, Schütz, C, Kallinich, T, Krause, K, Rietschel, C, Horneff, G, Kuemmerle-Deschner, J
Published 2013

PW02-041 - Canakinumab treatment regimens in CAPS-patients

by Hofer, F, Endres, T, Kortus-Götze, B, Blank, N, Weißbarth-Riedel, E, Schuetz, C, Kallinich, T, Krause, K, Rietschel, C, Horneff, G, Kuemmerle-Deschner, J
Published 2013

PW02-040 - Low-penetrance NLRP3 variants

by Endres, T, Hofer, F, Goldbach-Mansky, R, Hoffman, HM, Blank, N, Krause, K, Rietschel, C, Horneff, G, Lohse, P, Kuemmerle-Deschner, J
Published 2013

Canakinumab treat-to target strategies increase complete response rate in CAPS

by Kuemmerle-Deschner, J, Hofer, F, Endres, T, Kortus-Goetze, B, Blank, N, Weißbarth-Riedel, E, Schuetz, C, Kallinich, T, Krause, K, Rietschel, C, Horneff, G, Benseler, SM
Published 2015

International experience of pregnancy outcomes in auto-inflammatory syndromes treated with Interleukin-1 inhibitors

by Youngstein, T, Hoffmann, P, Lane, T, Williams, R, Rowczenio, D, Ozdogan, H, Urgurlu, S, Ryan, J, Harty, L, Riminton, S, Headley, A, Roesler, J, Blank, N, Michler, C, Simon, A, Hawkins, P, Lachmann, H
Published 2015